SYTL2 promotes metastasis of prostate cancer cells by enhancing FSCN1-mediated pseudopodia formation and invasion

• Published in: Journal of translational medicine Vol. 21; no. 1; pp. 303 - 15
• Main Authors: Li, Zean, Tao, Yiran, Gao, Ze, Peng, Shirong, Lai, Yiming, Li, Kaiwen, Chen, Xu, Huang, Hai
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 05.05.2023; BioMed Central; BMC
• Subjects: Actin; Antibodies; Carrier Proteins - genetics; Cell culture; Cell Line, Tumor; Cell Movement - genetics; Cytoskeleton; Data analysis; Diagnosis; FSCN1; Genomes; Health aspects; Humans; Lymph nodes; Lymphatic Metastasis; Male; Medical prognosis; Membrane Proteins - genetics; Metastases; Metastasis; Microfilament Proteins - genetics; MicroRNAs - genetics; Mobility; Paraffin; Prognosis; Prostate cancer; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Proteasomes; Protein binding; Proteins; Pseudopodia; Pseudopodia - metabolism; Risk factors; Survival analysis; Synaptotagmin; SYTL2; Transcriptomes; Tumor cells; China; United States > US; Japan; FSCN1; Pseudopodia; Metastasis; Prostate cancer; SYTL2

Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis...